Investigators at Tel Aviv University and the Rabin Medical Center in Israel assessed the impact of cannabis exposure on motor symptoms and pain parameters in patients with Parkinson’s disease.
Researchers reported that cannabis inhalation was associated with improved symptoms 30-minutes following exposure. “Cannabis improved motor scores and pain symptoms in PD patients,” authors concluded.
A prior Israeli trial evaluating the impact of cannabis on PD patients reported “significant improvement after treatment in tremor, rigidity, and bradykinsea (slowness of movement) … [as well as] significant improvement of sleep and pain scores.”
Over 20,000 Israeli patients receive cannabis under a federally regulated program. Over 90 percent of those participants report significant improvements in pain and function as a result of their medicinal cannabis use.
An abstract of the study, “Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson’s disease,” is available online here.
Australian lawmakers are anticipated to approve landmark legislation in the coming months allowing for the production and use of cannabis for therapeutic purposes.
The legislation, which is backed by Australia’s Prime Minister, Health Minister, and leading political parties, amends national drug laws to permit for the licensed cultivation and distribution of medicinal cannabis.
The move by Parliament follows recent efforts by several Australian territories to provide patients participating in clinical trials with access to the plant.
“This government understands that there are some Australians suffering from severe conditions for which cannabis may have applications,” Health Minister Sussan Ley told Parliament this week. “[W]e want to enable access to the most effective medical treatments available.”
She added, “Allowing controlled cultivation locally will provide the critical missing piece for a sustainable legal supply of safe medicinal cannabis products for Australian patients in the future.”
To date, only Canada, Israel, and the Netherlands federally license private growers to provide medical marijuana to qualified patients. Colombia, Jamaica, and Puerto Rico are also expected to begin licensing medical marijuana manufacturing in the near future.
In 2013, Uruguay officials approved legislation authorizing the retail production and sale of cannabis to those age 18 and older. Consumers in that country are anticipated to be able to begin purchasing cannabis at state-licensed pharmacies by mid-2016.
Plenty of marijuana law reform legislation was introduced in state legislatures across the country this week! We have news out of Georgia, Kansas, Maryland, New Hampshire, Utah and Washington. Plus some news from abroad! Keep reading below to get the latest news in marijuana law reform from this week.
Chile: A medical marijuana farm in the country was officially “inaugurated” this week, signifying a growing approval of medical marijuana use in the region. The farm is the largest medical marijuana plantation in Latin America and will provide medicine to about 4,000 patients in the country.
Israel: The Knesset Labor, Social Affairs and Health Committee held a joint session with the Anti-Drug and Alcohol Committee to discuss reform of the country’s medical marijuana regulations. Currently only a small number of doctors can prescribe the medicine and there is a shortage of supply so officials are looking to expand physician privileges to prescribe cannabis.
“People are dying and suffering [from lack of the drug],” they said. “We have heard grandiose promises, but so far there are no answers. There is plenty of bureaucracy that doesn’t know how to deal with individual cases.
Mexico: After a series of public debates and bipartisan support, a bill to allow the importation of medical marijuana products is expected to pass by May.
“The bill, proposed by Institutional Revolutionary Party Senator Cristina Diaz, aims to change Mexican laws to allow the import of medical marijuana products to help the roughly 5,000 medical patients currently without access to such drugs.”
Georgia: A newly introduced Senate Resolution seeks to place a constitutional amendment on the November 2016 ballot to regulate adult marijuana use.
SR6 would allow voters to decide if they wish to regulate the commercial cultivation, processing, and retail of marijuana to adults over the age of 21. You can read the full text of this proposal here. To contact your lawmakers and urge their support for the measure, click here.
Kansas: Senate lawmakers are considering legislation, HB 2049, to amend various penalties and regulations specific to marijuana possession and use.
House Bill 2049 seeks to a) establish a statewide research program to oversee the production of industrial hemp, b) authorize the limited use of cannabidiol for therapeutic purposes, and c) reduce criminal penalties for first-time marijuana possession offenses from a Class A misdemeanor (punishable by up to one year incarceration and a $2,500 fine) to a Class B misdemeanor (punishable by no more than six months in jail and a $1,000 fine).
Click here to learn more and urge your lawmakers to support this legislation.
Maryland: January 21, members of the Maryland House and Senate voted to override a 2015 veto and to decriminalize the possession of marijuana paraphernalia.
Senate Bill 517 amends existing criminal penalties regarding the possession of marijuana-related paraphernalia from a misdemeanor, punishable by possible jail time, to a civil violation. However, amended language also includes a provision establishing a civil fine of up to $500 for offenses involving the use of marijuana in public. NORML and our affiliates will be working in the future to amend this penalty.
On January 27th, the House Criminal Justice and Public Safety Committee will be voting on the three separate bills that would legalize various amounts of marijuana.
For more information or to urge your lawmakers to support legalization in New Hampshire, click here.
House bill 1631, legislation to decriminalize the possession of small amounts of marijuana, is also pending in the House of Representatives.
Utah: SB 73, the Medical Cannabis Act, sponsored by Sen. Mark Madsen, was introduced this week and seeks to amend state law to permit for the state-licensed cultivation of cannabis, including strains with higher THC content, for the manufacturing of medicinal products and/or herbal preparations.
Under a 2014 law, qualifying patients are permitted to possess cannabis extracts that contain more than 15 percent CBD and no more than 0.3 percent THC. However, the law provides no legal supply source for these products and, as a result, it has largely failed to meet the needs of patients.
Competing legislation seeks to only permit the use of CBD in pill or oil form and prohibits any form of THC.
Click here to contact your lawmakers and urge them to support SB 73!
Washington: Newly introduced legislation, HB 2629, The Adult Home Grow & Criminal Reduction Bill would permit adults to grow a limited number of marijuana plants for personal use.
Click here to urge your lawmakers in Washington to support these measures.
Additional information for these and other pending legislative measures may be found at our #TakeAction Center!
** A note to first time readers: NORML can not introduce legislation in your state. Nor can any other non-profit advocacy organization. Only your state representatives, or in some cases an individual constituent (by way of their representative; this is known as introducing legislation ‘by request’) can do so. NORML can — and does — work closely with like-minded politicians and citizens to reform marijuana laws, and lobbies on behalf of these efforts. But ultimately the most effective way — and the only way — to successfully achieve statewide marijuana law reform is for local stakeholders and citizens to become involved in the political process and to make the changes they want to see. Get active; get NORML!
The administration of liquid cannabis extracts containing THC is associated with the mitigation of various symptoms of Alzheimer’s-related agitation and dementia, according to observational trial data published online ahead of print in The Journal of Alzheimer’s Disease.
Israeli investigators assessed the use of cannabis oil as an adjunct pharmacotherapy treatment in ten Alzheimer’s disease patients over a period of several weeks. Researchers reported that drug administration was associated with a significant reduction in patients’ symptom severity scores. Specifically, cannabis oil ingestion corresponded with decreased levels of aggression, irritability, apathy, and delusions.
Investigators concluded, “Adding medical cannabis oil to Alzheimer’s disease patients pharmacotherapy is safe and a promising treatment option.”
The administration of dronabinol (oral synthetic THC in pill form) has previously been reported to reduce Alzheimer’s-induced agitation and improve weight gain, while preclinical studies have theorized that cannabinoids may be neuroprotective against the onset of the disease.
An abstract of the study, “Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An open label, add-on, pilot study,” appears online here.
Inhaling cannabis is associated with the remission of refractory idiopathic angioedema, according to a clinical report published in the journal Case Reports in Immunology. Angioedema is a condition characterized by rapid swelling under the skin in regions around the face and throat, which may result in airway obstruction or suffocation.
Investigators from the Soroka University Medical Center in Israel reported on the progress of a 27-year-old male patient with life-threatening, recurrent angioedema of unknown origin. Doctors placed the patient on a regiment of 20 grams of inhaled cannabis monthly after he failed to respond favorably to prescribed steroids and antihistamines.
Authors reported: “The use of inhaled cannabis resulted in a complete response, and he has been free of symptoms for 2 years. An attempt to withhold the inhaled cannabis led to a recurrent attack within a week, and resuming cannabis maintained the remission, suggesting a cause and effect relationship.”
They concluded: “This is the first report in which a cannabis product for the treatment of refractory idiopathic angioedema was associated with an excellent clinical response. … More research into the exact mechanism of action of cannabis products in cases of idiopathic angioedema and on the modulation of the immune response in general is indicated.”
The Israeli government has authorized the limited production and distribution of marijuana as a medical treatment since 2011, and preparations of the plant are expected to be available in pharmacies imminently.
Full text of the report, “Life threatening idiopathic recurrent angioedema responding to cannabis,” appears online here.